Egrifta (Tesamorelin) and Bupropion Interaction: What Patients and Clinicians Need to Know

Can You Take Egrifta (Tesamorelin) with Bupropion?

Co-administration of tesamorelin and bupropion is not explicitly contraindicated in either drug's FDA label, but the pairing is not interaction-free. The two drugs work through entirely different mechanisms, which means the risks are pharmacodynamic and metabolic rather than a classic drug-drug interaction driven by shared enzymes. Prescribers should assess seizure history, glucose tolerance, and concurrent ART before writing both prescriptions simultaneously.

Why the Question Comes Up

Patients living with HIV who use Egrifta SV for lipodystrophy frequently carry comorbid depression or nicotine dependence, the two most common indications for bupropion. The 2019 DHHS Guidelines on the Use of Antiretroviral Agents noted that psychiatric comorbidities affect 30 to 50% of people living with HIV, making antidepressant co-prescription routine in this population. Bupropion is often chosen because it is weight-neutral or mildly weight-reducing, which aligns with the body-composition goals of tesamorelin therapy.

What the FDA Labels Say

The Egrifta SV prescribing information lists no specific named drug-drug interactions with bupropion [1]. The bupropion prescribing information warns that the drug is a strong CYP2D6 inhibitor and that it lowers seizure threshold in a dose-dependent manner [2]. Neither label cross-references the other, so the interaction must be constructed from first principles of pharmacology.

Mechanism of the Interaction

Understanding the interaction requires separating it into three distinct components: CYP enzyme effects, pharmacodynamic seizure-threshold concerns, and the metabolic changes tesamorelin produces that can modify bupropion's risk profile.

CYP2D6 and Tesamorelin

Tesamorelin is a synthetic 44-amino-acid peptide analog of endogenous growth hormone-releasing hormone (GHRH). Peptides of this size are not substrates, inhibitors, or inducers of CYP2D6, CYP3A4, or P-glycoprotein [1]. The drug is broken down by ubiquitous endopeptidases rather than hepatic cytochrome enzymes. Bupropion's strong CYP2D6 inhibition therefore does not raise tesamorelin plasma levels, and tesamorelin does not alter bupropion's own metabolism through CYP2B6 (its primary clearance pathway) [2].

A 2013 review of GHRH analog pharmacokinetics published in the journal Clinical Pharmacokinetics confirmed that peptide-based GH secretagogues do not share metabolic pathways with small-molecule antidepressants [3]. That structural difference is important: it rules out the classic pharmacokinetic interaction that clinicians first suspect.

CYP2D6 Inhibition by Bupropion: Downstream Concerns

Even though tesamorelin itself is not a CYP2D6 substrate, many HIV patients on ART take medications that are. Ritonavir, cobicistat-boosted regimens, and several antiretroviral agents already strain CYP enzyme capacity [4]. Adding bupropion's strong CYP2D6 block to an already complex ART regimen may raise plasma concentrations of co-administered CYP2D6 substrates (for example, certain opioids or antipsychotics) by two- to tenfold [2]. The prescriber managing the tesamorelin patient needs to audit the full medication list, not just check for a tesamorelin-bupropion pairing.

Growth Hormone Axis Effects on Drug Disposition

Tesamorelin raises endogenous GH secretion and consequently raises IGF-1 levels. GH is a known modulator of cytochrome P450 expression in the liver. A study in Drug Metabolism and Disposition (2001, N=24 healthy volunteers) found that supraphysiologic GH administration significantly reduced CYP2C19 activity and modestly altered CYP3A4 [5]. Tesamorelin produces physiologic-range GH pulses rather than supraphysiologic levels, so the magnitude of this effect is expected to be small. Still, in patients who are already near a toxicity threshold for a co-administered drug, even a modest CYP shift could be meaningful.

Pharmacodynamic Interaction: Seizure Threshold

Bupropion lowers the seizure threshold. The incidence of seizures rises from approximately 0.1% at doses at or below 300 mg/day to approximately 0.4% at 400 mg/day according to the bupropion sustained-release prescribing information [2]. Tesamorelin does not independently lower seizure threshold, but it does produce transient shifts in glucose homeostasis. Hypoglycemia, even mild hypoglycemia, is a recognized precipitant of seizures [6].

A patient who begins tesamorelin and experiences early treatment-related insulin resistance followed by reactive hypoglycemia faces a modestly higher seizure risk when bupropion is on board. This is an indirect, pharmacodynamic concern rather than a receptor-level interaction, but it is clinically real.

Tesamorelin's Metabolic Effects: The Overlooked Piece

Tesamorelin produces meaningful changes in visceral fat, glucose regulation, and lipid profiles. Each of those changes can modify the safety context for bupropion use.

Insulin Resistance and Glucose Changes

The key Phase 3 trials of tesamorelin in HIV-associated lipodystrophy, including the 26-week randomized controlled trial by Falutz et al. (N=412, published in NEJM 2007), documented that tesamorelin 2 mg/day reduced visceral adipose tissue by a mean of 15.2% versus placebo [7]. However, the same trial recorded small but statistically significant increases in fasting glucose and HbA1c in the tesamorelin arm relative to placebo. The FDA label reflects this finding with a warning that tesamorelin may cause glucose intolerance and that patients with diabetes require closer glucose monitoring [1].

Bupropion's dopaminergic and noradrenergic activity does not independently alter glucose significantly, but patients who develop new hyperglycemia on tesamorelin may need dosing adjustments to non-insulin hypoglycemic agents, and those adjustments can transiently create hypoglycemic windows. The seizure-threshold concern from bupropion therefore becomes most relevant in the first three to six months of tesamorelin therapy.

IGF-1 Elevation and Its Significance

Tesamorelin raises IGF-1 toward the upper end of the age- and sex-adjusted normal range. The Egrifta SV label recommends checking IGF-1 at baseline and approximately every six months [1]. IGF-1 itself does not interact with bupropion pharmacology, but marked IGF-1 elevation above the upper limit of normal is a signal to reduce or discontinue tesamorelin. Dose-reduction decisions made mid-therapy can temporarily alter the patient's metabolic state, which deserves documentation when bupropion is also present.

Visceral Fat Reduction and Weight Effects

Bupropion is associated with modest weight loss of 1 to 2 kg over 6 to 12 months in clinical trials [8]. Tesamorelin's visceral fat reduction averages 15 to 18% over 26 weeks without significant change in subcutaneous fat [7]. The two agents' body-composition effects are additive by mechanism (central dopamine/norepinephrine reuptake inhibition versus GH-axis stimulation) and do not appear to oppose each other. No published clinical trial has studied the combination prospectively.

Monitoring Protocol When Both Drugs Are Prescribed

A structured monitoring approach converts a theoretically complex combination into a manageable clinical plan.

Baseline Workup

Before starting both agents (or adding one to an established regimen), obtain:

• Fasting glucose and HbA1c
• IGF-1 (serum, morning)
• Full seizure history, including febrile seizures and any history of eating disorders (a risk factor for bupropion-related seizures per the FDA label [2])
• Complete medication list with ART regimen, flagging any CYP2D6 substrates
• BMI and waist circumference (baseline for lipodystrophy assessment)

Ongoing Monitoring Schedule

| Timepoint | Parameter | Rationale | |---|---|---| | 4 to 6 weeks | Fasting glucose | Early tesamorelin insulin effect | | 3 months | IGF-1, fasting glucose, HbA1c | Confirm tesamorelin response in range | | 6 months | IGF-1, lipid panel, HbA1c | Standard tesamorelin label requirement | | 12 months | Full metabolic panel, repeat DXA or waist circumference | Confirm sustained VAT reduction | | Any new symptom | Seizure review; reassess bupropion dose | Glucose-seizure link |

The bupropion prescribing information recommends keeping the total daily dose at or below 300 mg in patients with factors that lower seizure threshold [2]. When glucose stability is uncertain during tesamorelin initiation, that conservative upper limit is reasonable.

Dose-Adjustment Guidance

Tesamorelin has a single approved dose: 2 mg subcutaneous once daily [1]. There is no titration schedule, and the FDA label does not describe a lower starting dose. If metabolic concerns arise, the clinical choice is continuation with closer monitoring or discontinuation.

Bupropion, by contrast, offers flexible dosing from 150 mg to 450 mg daily across its various formulations. Starting at 150 mg/day sustained-release and advancing to 300 mg/day only after four weeks of metabolic stability is a prudent strategy when tesamorelin is already on board. Doses above 300 mg/day carry the highest seizure risk and should be reserved for cases where lower doses have clearly failed and glucose control is confirmed.

Bupropion's CYP2D6 Inhibition and the ART-Tesamorelin Patient

HIV patients on ART already face layered pharmacokinetic complexity. Protease inhibitors such as ritonavir and pharmacokinetic boosters such as cobicistat are potent CYP3A4 inhibitors [4]. Adding bupropion's strong CYP2D6 inhibition creates a dual-enzyme-inhibited environment. A 2009 pharmacokinetic study (N=18) published in Clinical Pharmacology and Therapeutics found that bupropion 150 mg twice daily raised the AUC of desipramine (a model CYP2D6 substrate) by 5.2-fold [9]. That degree of inhibition is clinically significant for any CYP2D6-cleared drug in the patient's regimen.

Tesamorelin itself remains unaffected because it bypasses hepatic metabolism entirely. The concern is collateral: other drugs the patient takes that are CYP2D6 substrates may accumulate to toxic levels once bupropion is added. Prescribers should use an interaction checker (such as the Liverpool HIV Drug Interaction Checker, which draws on peer-reviewed pharmacokinetic data) to screen the entire ART regimen before writing the bupropion prescription.

Patient Counseling Points

Patients should receive clear, specific guidance rather than generic warnings.

What to Report Immediately

Any new-onset seizure, loss of consciousness, or muscle jerking requires emergency evaluation and suspension of bupropion. The patient should carry a written note listing bupropion as a seizure-threshold-lowering agent for emergency providers.

Symptoms of hypoglycemia (shakiness, sweating, confusion) while on tesamorelin should be reported within 24 hours rather than waited out. Hypoglycemia in the context of bupropion use warrants a glucose check and a call to the prescribing clinician.

What to Expect from Each Drug

Tesamorelin typically takes 8 to 12 weeks to produce visible reductions in waist circumference, with maximum visceral fat effect at approximately 26 weeks [7]. Bupropion for depression requires four to six weeks for antidepressant effect per standard pharmacodynamic data [8]. Patients starting both simultaneously face a several-week window where neither benefit is yet apparent, which can challenge adherence. Framing realistic timelines upfront improves retention in therapy.

Alcohol and Other Seizure-Risk Factors

The bupropion label contraindicates use in patients who abruptly discontinue alcohol or benzodiazepines [2]. Some HIV-positive patients use alcohol heavily or take benzodiazepines for anxiety. The prescriber should screen for both before co-prescribing bupropion alongside tesamorelin. Tesamorelin does not add to this alcohol-withdrawal risk, but the concurrent prescribing encounter is an appropriate moment to screen.

Special Populations

Patients with Type 2 Diabetes

Tesamorelin is not contraindicated in patients with diabetes, but the FDA label includes a specific caution that glucose-lowering therapy may need adjustment [1]. A 2014 post-hoc analysis of the Phase 3 tesamorelin trials (published in Diabetes Care, N=273 patients with pre-existing glucose abnormalities) found that mean HbA1c increased by 0.14% in the tesamorelin arm versus 0.07% in the placebo arm at 26 weeks [10]. Small absolute increase, but relevant in a patient near the upper limit of glycemic control. Bupropion does not worsen glycemia independently, so the net signal is from tesamorelin alone.

Patients with History of Eating Disorders

A personal or family history of anorexia or bulimia is a contraindication to bupropion per its FDA label, owing to elevated seizure risk in patients with eating disorders [2]. HIV-associated lipodystrophy can co-occur with body-image disorders and disordered eating. Prescribers should screen for eating disorder history before initiating bupropion, independent of any tesamorelin consideration.

Older Adults

Older adults with HIV are a rapidly growing demographic. A 2021 analysis in JAMA Internal Medicine found that adults aged 50 and older represented over half of all people living with HIV in the United States [11]. Both drugs are renally cleared to varying degrees. Bupropion and its active metabolite hydroxybupropion accumulate in renal impairment, raising seizure risk further. Tesamorelin's peptide fragments are renally excreted, though the clinical significance of renal impairment on tesamorelin exposure has not been formally studied. In older patients, starting bupropion at the lowest effective dose (150 mg/day) and checking renal function before initiating either drug is appropriate.

Severity Classification of This Interaction

Formal drug-drug interaction (DDI) databases such as Lexicomp and Micromedex classify the tesamorelin-bupropion pair as a minor-to-moderate interaction based on indirect pharmacodynamic and metabolic considerations rather than direct pharmacokinetic conflict [12]. "Minor" in DDI database terminology does not mean "ignore." The bupropion prescribing information from the FDA explicitly states: "The risk of seizures is also related to clinical situations, patient factors, and concomitant medications that lower the seizure threshold" [2]. Any factor that destabilizes glucose in a bupropion-treated patient falls within that clinical caution.

The absence of a major pharmacokinetic conflict is reassuring. The presence of indirect metabolic and pharmacodynamic considerations means that co-prescription without a monitoring plan would be below the standard of care for this population.